Adenoviral-mediated PTEN transgene expression combined with radiotherapy, chemotherapy and other cancer-suppressing genes has been used to treat prostate cancer cells to boost the antitumor effect [49], [50], [51], [52]. This evidence concerns the gene PTEN and prostate cancer.